Patents
Patents for A61K 38 - Medicinal preparations containing peptides (316,240)
05/2002
05/23/2002WO2001083720A3 23686, a novel human aminotransferase and uses therefor
05/23/2002WO2001083719A3 25692, a novel human o-methyltransferase family member and uses thereof
05/23/2002WO2001083513A3 Antisense modulation of inhibitor of dna binding-1 expression
05/23/2002WO2001082971A3 Cyclodextrin containing glycopeptide antibiotic compositions
05/23/2002WO2001082948A3 Uses of tgap7 for the modulation of leucocyte activation
05/23/2002WO2001081577A3 Dna encoding the prost 03 polypeptide
05/23/2002WO2001081373A3 Glycopeptide antibacterial compounds and methods of using same
05/23/2002WO2001080887A3 Methods and chemokin compositions for inducing an immune response
05/23/2002WO2001079444A3 Albumin fusion proteins
05/23/2002WO2001078692A3 Membrane delivery system
05/23/2002WO2001077687A3 Prion-binding peptidic ligands and methods of using same
05/23/2002WO2001076637A3 Peptide conjugates for drug delivery
05/23/2002WO2001076621A3 Methods and compositions for treating neoplasms
05/23/2002WO2001073028A3 A p-selectin glycoprotein ligand (psgl-1) binding protein and uses therefor
05/23/2002WO2001072837A3 Methods of modulating drug clearance mechanisms by altering sxr activity
05/23/2002WO2001072826A3 Oncogenic osteomalacia-related gene 1
05/23/2002WO2001072294A3 Method of treating hepatitis delta viral infection
05/23/2002WO2001064837A8 β NETRIN AND USES THEREOF
05/23/2002WO2001063295A3 Dpi-6, a therapeutic biomarker in neurological disorders
05/23/2002WO2001053506A3 Virus strains for the oncolytic treatment of cancer
05/23/2002WO2001049316A3 Use of a vector comprising a nucleic acid coding for an anti-angiogenic factor for treating corneal neovascularization
05/23/2002WO2001047946A9 GFRα1-RET SPECIFIC AGONISTS AND METHODS THEREFOR
05/23/2002WO2001044206A9 Pyrazine based inhibitors of glycogen synthase kinase 3
05/23/2002WO2001040469A3 Tick antigens and compositions and methods comprising them
05/23/2002WO2001040271A9 Cancer associated antigens and uses therefor
05/23/2002WO2001038346A3 Short peptides to target epithelial cells
05/23/2002WO2001037872A9 'bonzo' chemokine receptor antibodies and ligands
05/23/2002WO2001027289A3 Recombinant proteins and peptides for endotoxin biosensors, endotoxin removal, and anti-microbial and anti-endotoxin therapeutics
05/23/2002WO2001027077A3 Hydroxysulfonylalkylene-, phosphonoalkylene- or difluoro(phosphononon)methyl- substituted benzene, or benzofuran derivatives as non-peptidic cdc25 inhibitors
05/23/2002WO2000053210A9 Methods of treatment and prevention of restenosis
05/23/2002US20020062488 Methods and compositions for modulating the interaction between the apj receptor and the hiv virus
05/23/2002US20020062008 Novel human beta2 integrin alpha subunit
05/23/2002US20020062007 Adjusted hemoglobin for use as synthetic blood
05/23/2002US20020061923 Diacid isoindoleine amide derivative
05/23/2002US20020061911 Enantiomers of 6-amino EM-12 and method of use
05/23/2002US20020061909 Vitronectin receptor antagonist pharmaceuticals
05/23/2002US20020061906 Aerosol compositions
05/23/2002US20020061879 Nitrosated and nitrosylated alpha-adrenergic receptor antagonist compounds, compositions and their uses
05/23/2002US20020061874 Substituted lactam; gamma-secretase inhibitor; decreases production of beta-amyloid; treatment for Altzheimer's and Down's syndrome
05/23/2002US20020061866 Pharmaceutical compositions comprising in combination a bisphosphonate and a matrix metalloproteinase inhibitor
05/23/2002US20020061862 Inducible nitric oxide synthase for treatment of disease
05/23/2002US20020061860 Antisense oligonucleotide inhibition of specific histone deacetylase isoforms
05/23/2002US20020061859 Antisense oligonucleotides and antibodies which inhibit its expression or biological activity
05/23/2002US20020061852 Methods of therapy with thrombin derived peptides
05/23/2002US20020061851 Amino acid sequence of pyroglutamyl-leucinyl-lysinyl-cysteinyl-tyrosinyl-threoninyl-cysteinyl -lysinyl-gluta myl-prolinyl-methioninyl-threoninyl-serinyl-alaninyl-alaninyl-cysteine, in a peptide, is used as antitumor agent
05/23/2002US20020061850 Regulation of human transmembrane serine protease
05/23/2002US20020061849 Methods for treatment of diseases associated with inflammation under non-ischemic conditions
05/23/2002US20020061848 An specific polypeptides comprising a Chlamydia antigen and the use of such polypeptides for the serodiagnosis and treatement of Chlamydia infection
05/23/2002US20020061844 Administering to the patient for inhibiting Fc receptor binding of immunoglobulin a compound selected from aromatic, heteroaromatic, cyclic, bicyclic and an amino acid derivative or salt
05/23/2002US20020061843 Use of mCRP for delivery of materials into cells
05/23/2002US20020061842 Method for sterilizing a native collagen in liquid medium, sterile native collagen obtained, compositions containing it and uses
05/23/2002US20020061841 Asthma/allergy therapy that targets T-lymphocytes and/or eosinophils
05/23/2002US20020061840 Tripeptide compounds useful as selective inhibitors of aminopeptidase A and corresponding pharmaceutical compositions
05/23/2002US20020061838 Peptide pharmaceutical formulations
05/23/2002US20020061837 Bone morphogenetic protein and fibroblast growth factor compositions and methods for the induction of cardiogenesis
05/23/2002US20020061836 Modifying drug pharmacokinetics by altering the activity of steroid xenobiotic receptor(SXR) on expression levels of CYP2C8 or MDR1 cytochrome
05/23/2002US20020061834 Human G-protein Chemokine receptor (CCR5) HDGNR10
05/23/2002US20020061590 Nucleotide sequences coding transport protein for use treatment of hematopoietic and immunological defects
05/23/2002US20020061587 Treating cardiovascular disorders and tissue; obtain tissue, incubate with cytokines, graft somatic stem cells, monitor tissue adjustment in activity
05/23/2002US20020061585 Ribozymal nucleic acid
05/23/2002US20020061577 BMP-6 proteins
05/23/2002US20020061576 Tissue plasminogen activator-like protease
05/23/2002US20020061575 27803, a novel human adenylate kinase family member and uses therefor
05/23/2002US20020061573 Nucleotide seqences which code enzymatic polypeptide for use in diagnosis and treatment of cell propagation defects, pain, eating, urogenital and brain disorders, cachexia and diabetes
05/23/2002US20020061567 Nucleotide sequences coding polypeptide for use in diagnostics, forensics, gene mapping and detection of mutation
05/23/2002US20020061562 Nucleotide sequences coding enzymatic polypeptide for use in trestment of vision defects
05/23/2002US20020061559 Preferential protein for use in the diagnosis and treatment of cancers; antitumor agents; anticarcinogeneic agents
05/23/2002US20020061558 Mouse G protein coupled receptor EDG7
05/23/2002US20020061557 Composition for use in the diagnosis and treatment of fertility defects, mammary gland and prostate cancers, osteoporosis, urogenital disorders and grave's disease
05/23/2002US20020061553 Partners of the PTB1 domain of FE65, preparation and uses
05/23/2002US20020061551 Nucleotide sequences coding a regulatory protein for use in the treatment of tumors, arteriosclerosis, autoimmune and diseases, blood disorders, asthma, arthritis and leukemia
05/23/2002US20020061545 Streptococcus pneumoniae antigens and vaccines
05/23/2002US20020061527 Human DNA topoisomerase I alpha
05/23/2002US20020061525 Sequences of trail variants
05/23/2002US20020061521 Nucleic acids, proteins, and antibodies
05/23/2002US20020061336 Also comprising a hydrogel, for use in the treatment of a subject by particle injection
05/23/2002US20020061316 Immunotherapeutic stress protein-peptide complexes against cancer
05/23/2002US20020061304 Combined treatment with keratinocyte growth factor and epidermal growth factor inhibitor
05/23/2002US20020061302 Method for the treatment of diabetes
05/23/2002US20020061300 Method and composition for treating prostate cancer
05/23/2002US20020061299 Protecting tissues from ischemia/reperfusion injury via introducing/ expressing gene construct encoding thereapeutic antioxidant
05/23/2002US20020061296 Nond-denatured apoptin (with fusion protein or tag) as anticancer, anti-autoimmune disease therapeutic proteins (HIV TAT proteins)
05/23/2002US20020061293 Transduced human hematopoietic stem cells
05/23/2002US20020061292 Dietary or pharmaceutical composition for use for the prevention or treatment of hyperoxaluria
05/23/2002US20020061290 Administering ribavirin and/or interferon alpha-2b
05/23/2002US20020061281 Aerosolized anti-infectives, anti-inflammatories, and decongestants for the treatment of sinusitis
05/23/2002US20020059932 Method of use of monomeric insulin as a means for improving the reproducibility of inhaled insulin
05/23/2002DE10058164A1 Dilute solution of chymotrypsin in physiological solvent, useful as rinsing solution for prevention of capsule fibrosis during and/or after operative treatment of cataracts
05/23/2002CA2763223A1 Synergistic combinations comprising a renin inhibitor for cardiovascular diseases
05/23/2002CA2632696A1 Modified clostridial neurotoxins with altered biological persistence
05/23/2002CA2429897A1 M. tuberculosis chaperonin 10 and uses thereof
05/23/2002CA2429894A1 M. tuberculosis chaperonin 60.1 and uses thereof
05/23/2002CA2429460A1 Artery smooth muscle- and vein smooth muscle-specific proteins and uses therefor
05/23/2002CA2429455A1 Fat regulated genes, uses thereof, and compounds for modulating same
05/23/2002CA2429106A1 Treatment of sexual dysfunction with non peptide bombesin receptor antagonists
05/23/2002CA2429100A1 Parenterally administrable microparticles
05/23/2002CA2428837A1 Microspheres of pancreatic enzymes with high stability
05/23/2002CA2428802A1 Camptothecin compounds with a sulfhydryl group
05/23/2002CA2428754A1 Corticotropin releasing factor receptor 2 deficient mice and uses thereof
05/23/2002CA2428748A1 Cross-linked hyaluronic acid-laminin gels and use thereof in cell culture and medical implants